意大利Bracco
Bracco is an international Group active in the healthcare sector through Bracco Imaging (diagnostic imaging), Pharma (prescription and over the counter drugs), Acist Medical Systems (advanced injection systems based in Minneapolis), and the Centro Diagnostico Italiano diagnostic clinic in Milan. It has 2,800 employees and annual total consolidated revenues of approximately 960 million euro, of which 65% from international sales and it is present in 80 countries around the world.

Originally established as a pharmaceuticals company in 1927, over the years Bracco has intensified its commitment to innovative specialist research in imaging agents for diagnostic medicine. A key breakthrough came in the 1970s with the development of the iopamidol molecule, the first ready-to-use non-ionic contrast agent. In the wake of this success, at the end of the 1980s the Group launched a program for international expansion, notably in the USA, now Bracco Imaging’s primary market. Here, the Group operates through Bracco Diagnostics Inc. and Bracco Research USA, both based in Princeton, New Jersey, where its worldwide clinical development work is coordinated. Bracco has also established itself as a major player in Japan, Europe and China, where it has a factory and laboratories in Shanghai, and a sales office and clinical development labs in Beijing.

Its subsidiary Bracco Imaging is one of the world's leading companies in the diagnostic imaging, offering a product and solutions portfolio for the main applications (X-Rays, Magnetic Resonance, Ultrasound, Nuclear Medicine). The recent acquisition of E-Z-EM Inc, a major manufacturer of contrast agent and medical instruments for gastrointestinal radiology, has further increased Bracco Imaging's offer. With its three Research Centers, in Ivrea (Turin), Geneva and Princeton (New Jersey), Bracco has an international research network specialized in the imaging field. The company invests approximately 9% of reference turnover in its R&D work every year and has a portfolio comprising over 1500 patents.

The Bracco diagnostic imaging offer is completed by advanced contrast imaging system technology in the fields of cardiology and radiology developed by Acist Medical Systems. The company, which was acquired by the Bracco Group in 2001, has its corporate headquarters in Eden Prairie, Minnesota, with regional offices in Europe and Asia. Today it employs over 220 people worldwide and its advanced systems are used in over 40 countries in the most world-renowned centers. More than 4.5 million people around the world have had cardiovascular angiographic procedures using an ACIST system.

In Italy, through the Pharmaceuticals Division, Bracco Spa is a key player in many strategically important therapeutic fields, including gastroenterology, neurology, endocrinology and cardio-vascular pathology, where it markets own-brand drugs or pharmaceuticals under license. The Pharmaceutical Division is present in the territory through a network of 240 pharmaceutical representatives, supported by a diffused sales organization.
The Bracco brand is widely known in Italy for its over-the-counter products, both pharmaceutical and dietetics. The product range includes Cebion, Xamamina, Euclorina and the Alfa eye-drops product line.

Another important area of activity of the Bracco Group regards the healthcare services provided by the Centro Diagnostico Italiano, a polyclinic based in Milan, with 13 satellite units in the city and in Lombardy, which offers different services of prevention, diagnosis and personalized treatment, with a focus on radio-surgery and on day-surgery. With a 30 years experience, it offers a wide range of prevention, diagnosis and therapy services on day-surgery basis and riabilitation for an amount per year of 110.000 diagnostic procedures in 50 clinical specializations and 3,5 million analysis for 500 types of exams. Equipped with the very latest technological systems (such as the Cyberknife radiosurgery robot), the CDI is an accredited body of the Joint Commission International.